Contact US | Chinese
You Position: Home > Journal issue
Drug Evaluation Drug Evaluation

2023:

2022:

2021:

2020:

2019:

2018:

2017:

2016:

2015:

2014:

2013:

2012:

2011:

2010:

2009:

2008:

2007:

2006:

2005:

2004:

Drug Evaluation

Items 1-5 of 13
«Preious | of 3 |
1

Re-evaluation of cardiovascular safetyof incretin-based therapies

Drug Evaluation, , Issue 15,2014, Pages 53-58,68, doi:10.3969/j.issn.1672-2809.2014.15.011

2

Liraglutide protects pancreatic beta cellsand its early beneifts for type 2 diabetes

Drug Evaluation, , Issue 15,2014, Pages 38-43, doi:10.3969/j.issn.1672-2809.2014.15.008

3

Expert opinion on the clinical use of human insulin andanimal insulin

Drug Evaluation, , Issue 15,2014, Pages 8-10, doi:10.3969/j.issn.1672-2809.2014.15.003

4

Current status and future of incretin-based therapies for type 2 diabetes

Drug Evaluation, , Issue 15,2014, Pages 32-37, doi:10.3969/j.issn.1672-2809.2014.15.007

5

文摘

Drug Evaluation, , Issue 15,2014, Pages 6-6, doi:10.3969/j.issn.1672-2809.2014.15.001

Items 1-5 of 13
«Preious | of 3 |
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn